Lot BB20 · 10 mg vial · Freedom Diagnostics · reported 9 June 2026 . The bar shows where the reported result falls against Astramide’s published release criterion. The notch marks the criterion.
Within criterionAbove criterionNot on this COA
Test
Method
Criterion
Result
Result vs criterion
Status
Identity
LC-MS
LC-MS match to the labelled compound
Confirmed
WITHIN SPEC
Chromatographic purity
HPLC-UV
at or above 98.0%
99.32%
95at or above 98.0%100
WITHIN SPEC
Net content — Ac-SDKP
HPLC-UV
11.8 mg
80120
REPORTED
Net content — BPC-157
HPLC-UV
11.22 mg
80120
REPORTED
Endotoxin
LAL, USP <85>
below the 0.05 EU/mL assay sensitivity
Pass, 2 of 2 at ≤0.05 EU/mL
WITHIN SPEC
Appearance
Visual
white lyophilized powder
White Lyophilized Powder
WITHIN SPEC
Values are reported per vial or bottle unless otherwise noted. Every figure here is taken from the batch Certificate of Analysis and nothing else.
Certificate of Analysis
Body Protection Compound 157 + Thymosin Beta-4 Fragment · Lot BB20 · 10 mg vial · Lab No. 2606080482
Freedom Diagnostics · 1 page · served inline, not a screenshot
Quick reference
How to read this report
Same six keys on every Astramide product page. Only the values change.
1Lot numberMatch it to the number printed on your product label. If they differ, this report is not for your product.
2IdentityMass spectrometry confirms the molecule is the one on the label. It conforms or it does not. There is no partial result.
3Chromatographic purityThe share of the material that is the target peptide. A purity figure quoted without a method is not a purity figure.
4Net contentHow much compound is in each vial or bottle, as measured by the laboratory. A different question from purity.
5EndotoxinMeasured against a ceiling, not a floor. Sensitivity differs by laboratory, so results are not compared across labs.
6Laboratory, method, dateWho ran it, on what instrument, and when. A report with no named laboratory or no date is not a report.
Molecular profile
Body Protection Compound 157 + Thymosin Beta-4 Fragment, in structural terms.
Sequence
BPC-157:
GEPPPGKPADDAGLV
Thymosin Beta-4 Fragment (Ac-SDKP):
Ac-Ser-Asp-Lys-Pro
Molecular formula
BPC-157: C₆₂H₉₈N₁₆O₂₂ Ac-SDKP: C₂₀H₃₃N₅O₉
Molecular weight
BPC-157: approximately 1419.5 g/mol Ac-SDKP: approximately 487.5 g/mol
CAS number
BPC-157: 137525-51-0 Ac-SDKP: 127103-11-1
Structure type
Blend
Primary molecular target
BPC-157: Multiple experimentally investigated cellular signaling pathways, including endothelial and angiogenesis-associated signaling. Ac-SDKP: TGF-β/Smad-associated signaling, fibroblast-associated pathways, extracellular-matrix regulation, and endothelial-cell signaling. Because this is a combination research product, there is no single established molecular target shared by both components.
Physical form
Lyophilized powder
This research formulation contains two distinct peptide structures: BPC-157, a synthetic 15-amino-acid peptide, and Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline), an N-terminally acetylated tetrapeptide derived from Thymosin Beta-4. Independent LC-MS analysis of the tested product identified both BPC-157 and Ac-SDKP as the constituent analytes.
These are the individual molecular formulas of the two components rather than a single molecular formula for the combined formulation. Molecular weights are reported separately because this is a two-component research formulation.
Research profile
Where Body Protection Compound 157 + Thymosin Beta-4 Fragment appears in the literature.
Body Protection Compound 157 + Thymosin Beta-4 Fragment combines two analytically distinct peptides investigated across different areas of experimental biology.
BPC-157 has been investigated in preclinical models involving cellular signaling, endothelial responses, angiogenesis-associated pathways, cellular migration, and tissue-response mechanisms.
The Thymosin Beta-4-derived component identified in the tested formulation is Ac-SDKP. Ac-SDKP has been investigated experimentally in fibroblast biology, extracellular-matrix regulation, TGF-β/Smad signaling, inflammatory pathways, endothelial-cell migration, and angiogenesis-associated models.
The current COA establishes the presence of BPC-157 and Ac-SDKP, but does not establish that the combination produces synergistic or additive biological effects.
These are published research systems. They do not describe approved clinical applications, and they do not establish efficacy or safety in humans.
Cited literature
Vukojevic J et al., 2022. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. PMID 34380875. https://pubmed.ncbi.nlm.nih.gov/34380875/
Yildirim AK et al., 2026. Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery. J Clin Med. PMID 42123221. https://pubmed.ncbi.nlm.nih.gov/42123221/
Hannappel E et al., 2007. beta-Thymosins. Ann N Y Acad Sci. PMID 17468232. https://pubmed.ncbi.nlm.nih.gov/17468232/
Evidence level
Preclinical Research This is the appropriate classification because the research context described above is predominantly derived from laboratory and preclinical investigation. It should not be presented as established clinical efficacy.
Handling and storage
As supplied
Lyophilized powder in a sealed vial. Held in laboratory-rated freezers from arrival to shipment.
Storage
Store per the conditions printed on the vial label. Avoid heat, moisture and repeated temperature cycling.
Handling
For qualified professionals in controlled laboratory environments, following validated laboratory procedures.
What purity did this Body Protection Compound 157 + Thymosin Beta-4 Fragment batch achieve?
Lot BB20 was analysed by Freedom Diagnostics and returned chromatographic purity of 99.32% by HPLC with UV detection coupled to mass spectrometry. Identity was confirmed by mass spectral match. The full certificate is published on this page, and every figure shown here is taken from it.
How much Body Protection Compound 157 + Thymosin Beta-4 Fragment is in the vial?
This is a multi-component preparation, so content is reported per component: Ac-SDKP 11.8 mg (118% of label), BPC-157 11.22 mg (112.2% of label). Astramide publishes the measured figures rather than the label claim.
Was this Body Protection Compound 157 + Thymosin Beta-4 Fragment batch tested for endotoxins?
Yes. Endotoxin testing was performed using the Limulus Amebocyte Lysate assay in accordance with USP , and this batch returned Pass, 2 of 2 at ≤0.05 EU/mL. The result appears on the certificate published on this page.
How should Body Protection Compound 157 + Thymosin Beta-4 Fragment be stored for research use?
As supplied, the lyophilized powder should be held at -20°C and protected from light and moisture. Once reconstituted, store at 2-8°C and use within 14 to 30 days. Avoid repeated freeze-thaw cycles and follow the handling procedures appropriate to your laboratory.
What is the difference between research-grade and pharmaceutical-grade Body Protection Compound 157 + Thymosin Beta-4 Fragment?
These are separate classifications. Research-grade material is supplied for laboratory research use only and is not intended for human or animal consumption. Pharmaceutical-grade is an FDA classification that applies to drugs manufactured for human use. Astramide supplies research-grade material only.
How can I verify this Body Protection Compound 157 + Thymosin Beta-4 Fragment certificate independently?
The certificate was issued by Freedom Diagnostics under lot BB20, laboratory reference 2606080482. Quote that reference to the laboratory directly. The same document is published here in full, and is not summarised or reformatted by Astramide.
Research use only
This product is intended strictly for in-vitro laboratory research conducted by qualified professionals.
It is not intended for human or animal consumption, clinical use, or therapeutic application.
The statements on this page have not been reviewed by the FDA. These research peptides are not intended
to diagnose, treat, cure, or prevent any disease. Research Use Only.
Get It Now
This product has multiple variants. The options may be chosen on the product page
Added to your cart
Your cart is empty.
Your Privacy Choices
We use analytics and advertising tools to understand how visitors find us and which campaigns work. You can turn either off. Your choice is saved in this browser.
AnalyticsGoogle Analytics, Microsoft Clarity and order source tracking. Helps us see how the site is used and fix problems.
Off (browser signal)
AdvertisingMeta and X pixels, and server-side events. Opting out also opts you out of "sharing" and targeted advertising under state privacy laws.
Off (browser signal)
Your browser is sending a Global Privacy Control signal, so analytics and advertising are off. To change this, turn off the signal in your browser settings.
Strictly necessary cookies (cart, sign-in, checkout, entry acknowledgment) always stay on. See our Privacy Policy.
Know what's in it before you order.
Every Astramide batch is tested by an independent US lab. The report goes public before the batch goes on sale, so you can check the numbers first.
Independent US lab test on every batch
Full report published before it goes on sale
Kept frozen, shipped from Austin, Texas
GLP-3RLot 2026/02 · May 8, 2026
>99.9%purity by HPLC-UV/MS
90%Minimum 98.0%100%
Identity: Confirmed by mass specEndotoxin: Below 0.5 EU/mL
Pro Series
Pro Series
